AUVYRON EDUCATION
Retatrutide: Research Overview
Retatrutide is a triple receptor agonist targeting GIP, GLP-1 and glucagon pathways. Published research has evaluated its effects on body-weight outcomes and related metabolic measures.
Retatrutide Research Evidence
1. What Retatrutide Is
3. Major Clinical Programs
1. What Retatrutide Is
Retatrutide is a single investigational molecule that activates GIP, GLP-1 and glucagon receptors. Research has evaluated its effects on body weight, glucose regulation and related metabolic outcomes.
2. Regulatory Status
3. Major Clinical Programs
1. What Retatrutide Is
Retatrutide remains investigational and is not currently an FDA-approved medication. It continues to be evaluated in an extensive phase 3 clinical-development program.
3. Major Clinical Programs
3. Major Clinical Programs
4. Doses Evaluated in Research
Phase 2 studies evaluated retatrutide in adults with obesity and in people with type 2 diabetes. The phase 3 TRIUMPH program is examining obesity, diabetes, cardiovascular and kidney outcomes, sleep apnea, osteoarthritis and other obesity-related conditions.
4. Doses Evaluated in Research
4. Doses Evaluated in Research
4. Doses Evaluated in Research
The phase 2 obesity trial evaluated once-weekly target doses ranging from 1 mg to 12 mg, using gradual escalation in several groups. These schedules describe published trial methodology and are not dosing recommendations.
5. Reported Outcomes
4. Doses Evaluated in Research
5. Reported Outcomes
Published phase 2 research reported substantial, dose-dependent reductions in body weight over 24 and 48 weeks. Outcomes varied according to dose group, participant characteristics and study duration.
6. Safety Findings
4. Doses Evaluated in Research
5. Reported Outcomes
The most commonly reported adverse events were gastrointestinal and occurred primarily during dose escalation. Published studies also reported changes in heart rate and emphasized the need for continued evaluation of long-term safety.
Published Research Highlights
1. Phase 2 Obesity Trial
The 48-week phase 2 trial evaluated retatrutide in adults with obesity or overweight without diabetes. Published results showed dose-dependent body-weight reductions across the study groups.
2. Body-Weight Outcomes
At 48 weeks, the 12 mg group showed a mean body-weight reduction of 24.2%. At 24 weeks, the highest mean reduction reported was 17.5%. These figures are clinical-trial group averages and do not predict individual outcomes.
3. Phase 3 TRIUMPH Program
The TRIUMPH phase 3 program is evaluating retatrutide across obesity and related conditions, including cardiovascular and kidney outcomes, type 2 diabetes, sleep apnea and osteoarthritis.
4. Emerging Phase 3 Results
Company-reported phase 3 topline results have described average body-weight reductions of 28.3% at 80 weeks in TRIUMPH-1 and 28.7% at 68 weeks in TRIUMPH-4. These results are company announcements and should be distinguished from peer-reviewed publication.
5. Metabolic Outcomes
Research has also examined glucose regulation and related cardiometabolic measures. Phase 3 studies continue to evaluate outcomes in participants with obesity, prediabetes and type 2 diabetes.
6. Research Limitations
Retatrutide remains investigational and is not currently FDA-approved. Results should be interpreted according to the population studied, trial duration, dose group and whether findings are peer-reviewed or company-reported topline data.
Scientific References & Research Disclaimer
1. Research Sources
This guide summarizes peer-reviewed clinical research, registered clinical trials and official research updates related to retatrutide. Sources were selected to reflect both published evidence and the current status of ongoing clinical development.
2. Primary Publications
Key sources include the phase 2 obesity trial published in The New England Journal of Medicine, TRIUMPH studies registered on ClinicalTrials.gov and official Eli Lilly research communications.
3. Educational Use
This content is provided for educational and research-information purposes only. Retatrutide remains investigational and is not currently FDA-approved. It is not medical advice, dosing guidance or instructions for human use.
4. Research Use Only
For Research Use Only. Not for Human Consumption.
Quality. Innovation. Excellence.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.